Henri Lu

Oct 22, 2024 | onlinelibrary.wiley.com | Henri Lu |Brian Claggett |Milton Packer |Baylor Heart

Supporting Information Filename Description ejhf3487-sup-0001-Figures.docxWord 2007 document , 1.3 MB Appendix S1. Supporting Information. References 1, , , , , , et al.; CHARM Investigators. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: Results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. J Am Coll Cardiol 2012; 59: 1785–1795.

Sep 1, 2024 | onlinelibrary.wiley.com | Henri Lu |Brian Claggett |Milton Packer |Marc A. Pfeffer

Supporting Information Filename Description ejhf3414-sup-0001-Supinfo.docxWord 2007 document , 6.5 MB Appendix S1. Supporting Information. References 1, . Anemia and iron deficiency in heart failure: Current concepts and emerging therapies. Circulation 2018; 138: 80–98. https://doi.org/10.1161/CIRCULATIONAHA.118.030099 2, , , , , , et al.; CHARM Committees and Investigators.

Aug 30, 2024 | jamanetwork.com | Henri Lu |Brian Claggett |Milton Packer |Karl Swedberg

Key PointsQuestion  What are the effects of sacubitril/valsartan on hospitalizations of any cause in patients with heart failure (HF)? Findings  In this post hoc pooled analysis of the PARADIGM-HF and PARAGON-HF randomized clinical trials including 13 194 patients, sacubitril/valsartan significantly reduced the risk of all-cause hospitalization, primarily driven by lower rates of cardiac and pulmonary hospitalization.